ALX Oncology (NASDAQ:ALXO – Get Rating) and Lumos Pharma (NASDAQ:LUMO – Get Rating) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, profitability, risk, earnings, analyst recommendations, dividends and valuation.
Earnings & Valuation
This table compares ALX Oncology and Lumos Pharma's gross revenue, earnings per share and valuation.
Get
ALX Oncology alerts:
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio |
| ALX Oncology | $1.18 million | 481.02 | -$83.46 million | ($2.72) | -5.12 |
| Lumos Pharma | $230,000.00 | 307.37 | -$30.43 million | ($3.44) | -2.45 |
Lumos Pharma has lower revenue, but higher earnings than ALX Oncology. ALX Oncology is trading at a lower price-to-earnings ratio than Lumos Pharma, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares ALX Oncology and Lumos Pharma's net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets |
| ALX Oncology | N/A | -31.38% | -29.66% |
| Lumos Pharma | N/A | -33.81% | -29.78% |
Institutional and Insider Ownership
89.4% of ALX Oncology shares are held by institutional investors. Comparatively, 38.4% of Lumos Pharma shares are held by institutional investors. 49.9% of ALX Oncology shares are held by insiders. Comparatively, 15.9% of Lumos Pharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Volatility & Risk
ALX Oncology has a beta of 2.21, suggesting that its stock price is 121% more volatile than the S&P 500. Comparatively, Lumos Pharma has a beta of 1.23, suggesting that its stock price is 23% more volatile than the S&P 500.
Analyst Recommendations
This is a summary of current ratings and recommmendations for ALX Oncology and Lumos Pharma, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
| ALX Oncology | 0 | 1 | 6 | 0 | 2.86 |
| Lumos Pharma | 0 | 0 | 3 | 0 | 3.00 |
ALX Oncology currently has a consensus target price of $39.83, suggesting a potential upside of 185.95%. Lumos Pharma has a consensus target price of $24.00, suggesting a potential upside of 185.04%. Given ALX Oncology's higher possible upside, research analysts plainly believe ALX Oncology is more favorable than Lumos Pharma.
Summary
ALX Oncology beats Lumos Pharma on 10 of the 13 factors compared between the two stocks.
About ALX Oncology
(Get Rating)
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hodgkin's lymphoma, as well as a range of solid tumor indications, including head and neck squamous cell carcinoma, human epidermal growth factor receptor 2 (HER2) positive gastric/gastroesophageal junction carcinoma, HER2-expressing breast cancer, and other solid tumors. The company's pre-clinical products include ALTA-002, a SIRPa TRAAC that offers ways to engage the innate and adaptive immune response to cancer. ALX Oncology Holdings Inc. has a collaboration agreement with Merck for a Phase 2 trial evaluating ALX148 in combination with pembrolizumab with and without chemotherapy in patients with head and neck cancer; Zymeworks on a Phase 1 trial evaluating ALX148 with the HER2-targeting bispecific antibody zanidatamab in patients with HER2-expressing breast cancer and other solid tumors; and Tallac Therapeutics for the development, manufacturing and commercialization of a novel class of cancer immunotherapeutics. It also has a license agreement with Selexis SA and Crystal Bioscience, Inc. The company was founded in 2015 and is headquartered in South San Francisco, California.
About Lumos Pharma
(Get Rating)
Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone secretagogue ibutamoren, which is in Phase 2 clinical trial for the treatment of pediatric growth hormone deficiency and other rare endocrine disorders. The company is headquartered in Austin, Texas.
Receive News & Ratings for ALX Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ALX Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
